Nurse Practitioner Registered

CURRICULUM VITAE

Kevin John Lagman, MBA, MSN, APRN, FNP-C

DEMOGRAPHIC INFORMATION:

Current Appointments:

Advanced Practice Provider, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 09/2018 - present Personal Data:

Office

The University of Texas MD Anderson Cancer Center

1220 Holcombe Blvd.

ACB7.2540, Unit Number: 1274

Houston, TX 77030

Phone: 713-***-****

Fax: 713-***-****

Email: ********@**********.***

Educational and Training:

Master of Business Administration with a Concentration in Healthcare Services, DeVry University

– Keller Graduate School of Management, Chicago, IL, 05/2016 – 03/2019 Master of Science in Nursing, University of Texas Health Science Center at Houston – School of Nursing, Harris Health Houston, Nurse TX, Residency 08/2014 Program, – 12/2015 Harris Health System – Ben Taub General Hospital, 07/2012 – 07/2013

Bachelor of Science in Nursing, Praire View A&M University – School of Nursing, Houston, TX, 01/2010 – 05/2012

Associate of Science in Life Science, Minor in Music – Voice and Piano, San Jacinto College, Pasadena, TX, 01/2009 – 12/2009

Associate of Arts in General Studies, San Jacinto College, Pasadena, TX, 01/2006 – 08/2008 Professional Experience:

Past Appointments

Family Nurse Practitioner, CVS MinuteClinic, Houston and Pearland, TX, 07/2018 – 03/2019 Independent Contractor, Home Health Nurse Practitioner, Signify Health, Texas, 07/2018 – 08/2018

Clinic Manager, South Austin Clinics – Brodie Lane, Kyle, and Dripping Springs, Rite Aid RediClinic, Austin, TX, 01/2018 – 06/2018

Kevin John Lagman, MBA, MSN, APRN, FNP-C

Page 2 of 4

Family Nurse Practitioner, Atascocita Clinic and South Houston Float Clinician, Rite Aid RediClinic, Houston, TX, 03/2016 – 12/2017

Registered Nurse Clinician II, Department of Medical Intensive Care Unit, Harris Health System – Ben Taub General Hospital, Houston, TX, 11/2013 – 10/2014 Registered Nurse Clinician I & II, Department of Medical-Surgical Unit, Harris Health System – Ben Taub General Hospital, Houston, TX, 07/2012 – 11/2013 Consultantships

PROVENGE® (sipuleucel-T) Consulting/Advisory Board, Dendreon Pharmaceuticals LLC, Houston, TX, 2019 – present

AstraZenica Consulting/Advisory Board, Houston, TX, 2020 – present Institutional Committee Activities

Genitourinary Immunotherapy Toxcity Team, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 08/2019 – present

Genitourinary Advanced Practice Provider Task Force, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 09/2018 – present

Epic Prostate Group, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 – present Unit Falls Champion, Department of Medical Intensive Care Unit, Harris Health System – Ben Taub General Hospital, Houston, TX, 11/2013 – 10/2014 Community of Practice Representative, Department of Medical-Surgical Unit, Harris Health System – Ben Taub General Hospital, Houston, TX, 11/2012 – 11/2013 Epic Champion, Department of Medical-Surgical Unit, Harris Health System – Ben Taub General Hospital, Houston, TX, 11/2012 – 11/2013

EDUCATIONAL ACTIVITIES:

Mentoring:

1. Arielle Olivares, APRN, NP, Advanced Practice Provider, MD Anderson Cancer Center, 03/2020 – present

2. Renju Sebastian, APRN, NP, Advanced Practice Provider, MD Anderson Cancer Center, 12/2019 – 01/2020

3. Jessica Gibson, APRN, FNP, Family Nurse Practitioner, Rite Aid RediClinic, 01/2018 – 06/2018

4. Sarah Lai, APRN, FNP, Family Nurse Practitioner, Rite Aid RediClinic, 2016 – 2018 5. Tabish Dhukka, APRN, FNP, Family Nurse Practitioner, Rite Aid RediClinic, 2017 – 2018 6. Kosisochi Alimole Agube, APRN, FNP, Clinic Manager, Rite Aid RediClinic, 2016 – 2018 7. Brittaney Pinson Shaw, APRN, FNP, Clinic Manager, Rite Aid RediClinic, 2016 – 2018 8. LaCheria Van Buren, APRN, FNP, Clinic Manager, Rite Aid RediClinic, 2017 – 2018 9. Tina de los Santos, RN, Nurse Clinician, Harris Health System, 2012 – 2013 Kevin John Lagman, MBA, MSN, APRN, FNP-C

Page 3 of 4

CLINICAL ACTIVITIES:

Certifications and Licensures:

Board Certified Family Nurse Practitioner, American Association of Nurse Practitioners (AANP), 12/2015 – present

Basic Life Support (BLS) Certification, American Heart Association, 2010 – present Registered Nurse License, Texas Board of Nursing, 819637, 06/2012 – present Advanced Practice Registered Nurse License, AP130532, 03/2016 – present Drug Enforcement Administration (DEA License), TX, ML4913441, 08/2018 – present Credentialed in Bone Marrow Aspiration and Biopsy Procedures, MD Anderson Cancer Center, 03/2019 – present

Clinical Management of Patients Enrolled in the Following Trials: 1. Randomized Phase II Study of Olaparib Maintenance Following Cabazitaxel-Carboplatin Induction Chemotherapy in Men with Aggressive Variant Prostate Cancer (AVPC), 2017- 0133, 2017, AstraZeneca, Moon Shot Program; Principal Investigator: Ana Aparicio, MD 2. A Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men with Metastatic Castrate Resistant Prostate Cancer, 2014-0386, 2014 – present, Bristol-Myers Squibb, MDACC, Janssen Research & Development, LLC, Sanofi US Services Inc; Principal Investigator: Ana Aparicio, MD

3. A Phase 2 Trial of Nivolumab Plus Ipilimumab in Men with Metastatic Castration- Resistant Prostate Cancer, 2016-0848, 2017 – present, Bristol-Myers Squibb; Principal Investigator: Padmanee Sharma, MD, PhD

4. A Phase 1b-2 Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer, 2017-0952, 2018 – present, Janssen Research and Development; Principal Investigator: Sumit Subudhi, MD, PhD 5. A Pilot Presurgical Study of Daratumumab (CD38 antagonist) in Men with High-Risk Localized Prostate Cancer Followed by Radical Prostatectomy, 2017-0103, 2016 – 2019, Janssen Research & Development, LLC; Principal Investigator: Sumit Subudhi, MD, PhD 6. A pilot trial to explore the link between immunological changes, efficacy, safety and tolerability of durvalumab (MEDI4736) plus tremelimumab in chemotherapy-naive men with metastatic castration-resistant prostate cancer (CRPC), 2016-0769, 2016 – 2019, AstraZeneca; Principal Investigator: Sumit Subudhi, MD, PhD 7. A Phase 2, Study of Apalutamide and Abiraterone Acetate in Castration-Resistant Bone Metastatic Prostate Cancer Patients Evaluating a Predetermined Biomarker Signature, 2017-0060, Janssen Scientific Affairs, LLC, 1/31/2018 – 1/30/2021; Principal Investigator: Eleni Efstathiou, MD, PhD

8. A Phase 2 Course Determining Study for Men with Hormone-Naïve Metastatic Prostate Cancer (HNMPCa), 2018-0533, 2019 – present; Principal Investigator: Paul Corn, MD CONFERENCES AND SYMPOSIA:

Conferences/Symposia:

1. American Society of Clinical Oncology (ASCO), Genitourinary Cancers Symposium, San Francisco, CA, 03/2020

2. 2019 Advanced Practice Provider Oncology Summit, San Francisco, CA, 08/2019 Kevin John Lagman, MBA, MSN, APRN, FNP-C

Page 4 of 4

3. 13th Update on the Management of Genitourinary Malignancies, MD Anderson Cancer Center, 11/2018

4. Pri-Med Regional Conference, Los Angeles, CA, 10/2017 5. Pri-Med Regional Conference, New York, NY, 11/2018 Institutional Presentations:

1. Screening and Management of Germline and Somatic Testing in Prostate Cancer, 02/2020

Contact this candidate